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Abstract   
Hodgkin Lymphoma (HL) is a B-Cell neoplasia with a favourable outcome in responding 
patients. However, despite the efficacy of first line therapy about 30% of patients eventually 
relapse or are refractory (R/R). Recently, the immune checkpoint inhibitor (CI) nivolumab 
demonstrated good activity in R/R HL patients although the complete response (CR) rate was 
less than 20%. The efficacy of nivolumab is strictly related to the host degree of immune 
competence, which is greatly impaired in heavily pre-treated HL patients after autologous 
stem cell transplantation (ASCT). To enhance the activity of CI, we explored the feasibility of 
the infusion of autologous lymphocytes (ALI) in combination with the pre-emptive 
administration of nivolumab, early post-ASCT, in patients affected by R/R HL. Eight patients 
(median age 29, range 18-56) with active R/R disease, who had already failed at least two 
chemotherapy lines and Brentuximab, were eligible for the trial. HL patients underwent early 
lymphocyte apheresis, with a target cell dose of 5x107 CD3+/kg. All patients then received 
ASCT with FEAM conditioning followed by ALI at a median time of 14 days after infusion, 
starting with 1x104 CD3+ cells/kg in the first infusion to a maximum of 1x107cells/kg in the 
fourth and last infusion. Each ALI was followed after 48 hours by the administration of 
nivolumab 240 mg flat dose. As a control cohort, two patients, in CR after second line 
chemotherapy, were given ALI only, without nivolumab.  
No grade 3 or 4 adverse events were recorded. All treated patients achieved negative PET scan 
after immunotherapy and are alive and disease-free after a median follow-up of 20 months. 
Two patients did receive allogeneic stem cell transplantation while in CR. Notably, compared 
to control patients, a faster expansion/reconstitution of highly differentiated NK cells 
was observed as well as a quicker T-cell recovery. These data suggest the potential role of PD-1 
receptor in the direct or indirect control of NK cell maturation/development and, probably, NK 
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anti-tumor activity. Thus, the combination of adoptive cell therapy with CI may represent a 





Hodgkin lymphoma (HL) is a lymphoid malignancy of B-cell origin with a high cure rate.1 
However, despite the efficacy of frontline therapy, about 30% of patient are refractory or 
relapse.2 In this subset, standard salvage treatment includes high-dose chemotherapy followed 
by autologous stem cell transplantation (ASCT).3  However, in order to be effective, ASCT 
should be performed  in chemoresponsive patients.3-5 Unfortunately, 30-50% of patients 
treated with salvage chemotherapy fail to achieve at least PR and Brentuximab-Vedotin (BV, 
an anti-CD30 immuno-conjugated antibody) is able to induce a response in only  30-50% of 
cases.6,7 Indeed, HL patients not achieving at least a partial response after second or third line 
chemotherapy have a poor prognosis.8  
Recently, the clinical application of immune checkpoint inhibitors (CI), in particular the PD-1 
targeting antibody nivolumab, has dramatically improved the prognosis of patients with 
advanced phase solid tumors.9 Nivolumab has also shown promising results in HL patients 
relapsing after ASCT and is currently approved for this setting. Unfortunately, the expected CR 
rate is only about 20% and median PFS is about 18 months, with no evidence of plateau.7,8,10,11 
Earlier administration of PD-1 targeting antibodies as post-ASCT consolidation may be more 
effective in selected patients, as observed with post-ASCT BV therapy.12 Moreover, several 
reports have highlighted the importance of patient immune-competence to achieve durable 
response with anti-PD-1 immunotherapy.13-15 In this view,  ASCT, especially in heavily pre-
treated patients, leads to a prolonged and deep immunosuppression.13   
In solid oncology, re-infusion of previously criopreserved unselected lymphocytes has been 
reported to boost T-cell count during radio and chemotherapy.16 To the best of our knowledge, 
such strategy has not been described for patients with hematological malignancies undergoing 
ASCT. 
Several lymphocyte populations have been shown to play a role in the complex 
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immunological mechanism of checkpoint inhibitors therapy.17 
Notably Reed Sternberg cells display a low/absent expression of HLA I-II complex thus 
excluding a major contribute of T lymphocyte subpopulations in response to PD-1/PDL-1 
blockade in HL setting.18 In cancer immunotherapy, Natural killer (NK) lymphocytes represent 
important innate effector cells able to kill tumor cell targets not expressing HLA class I 
molecules.19  
The aim of this small study was to assess the feasibility of early post ASCT CI therapy supported 
by unselected autologous lymphocytes infusions (ALI) and to evaluate post-ASCT 
immunoreconstitution with specific reference to NK cells. Our results show a very good clinical 
response rate associated with the fast expansion of highly differentiated NK cells after ASCT, 
suggesting that PD-1 receptor may have a role in accelerating NK cell maturation and, 
probably, in their anti-tumor activity. The combination of adoptive cell therapy with pre-




Primary endpoint of this study was to investigate the feasibility and toxicity of  post-ASCT 
nivolumab immunotherapy with the support of autologous lymphocyte reinfusions (ALI) in 
R/R HL  patients. Secondary clinical endpoint was the assessment of the efficacy of the 
strategy. 
A supplementary b io lo g ic a l  endpoint was the immunophenotypic evaluation of peripheral 
blood lymphocyte subpopulations, performed pre- and post-adoptive immunotherapy and CI 




Selection of patients, study population and treatment  
High risk HL patients (i.e. patients resistant to first line ABVD or showing early relapse) 
underwent steady-state unselected lymphocyte apheresis, with a target cell dose of 5x108 
CD3+/kg. They subsequently received salvage therapies including BV if necessary. Patients 
failing to achieve CR were enrolled in the treatment group whereas responding patients were 
included in the control group. All patients underwent ASCT conditioned with FEAM 
chemotherapy (see supplementary materials). The protocol outline is shown in Figure 1. 
Eight R/R HL patients potentially candidate to ASCT failing to achieve at least a PR after three 
lines of therapy including BV were included in the treatment cohort and received ALI plus 
nivolumab 240 mg flat dose, delivered 48 hours after each ALI. Two patients achieving CR 
before ASCT with either IGeV salvage chemotherapy or third line BV, did receive ALI only, 
without nivolumab, serving as a control group. In both groups the same peripheral blood 
analysis was performed at the same time points (see below for details).  
The number of planned ALI for each patient was four. After ASCT, the first ALI was performed 
at a median of 14 days after stem cell reinfusion (range 12-16), with at least 3 days wash out 
from the last G-CSF administration. Second ALI was delivered after 14 days and the other two 
infusions took place every three weeks.  
For safety reasons CD3+ dosing was incremental, with an increase of 1 log for each of the 4 
planned infusion (i.e 1x 104/Kg up to 1X107/Kg). Furthermore, the starting dose of cycle 1 was 
planned to increase by one log every four patients if no grade >2 adverse events were 
observed. Thus, the first four patients received 1x104 CD3+/kg in the first infusion and then we 
escalated the dose to 1x105 CD3+/kg. The schedule of ALI reinfusion and CI treatment is 
detailed in Figure 2.  
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Assessment of disease  response was performed in all patients after the first two cycles of 
nivolumab and 21 days after completion of the fourth ALI + nivolumab. Patients achieving CR 
were offered allogeneic stem cell transplant (HSCT), if feasible.  
 
Lymphocyte subpopulations analysis 
To assess immune-reconstitution, lymphocyte subpopulation analysis has been performed on 
peripheral blood samples by flow cytometry (BD-FACSCanto II cytometer). Lymphocyte 
subpopulations have been assessed at the following timepoints: 2 hours before and 48 hours 
after each of the four scheduled ALI and, in treatment group only, 48 hours after each 
nivolumab administration. 
Single platform absolute counts of major lymphocyte subsets are performed by standard 
peripheral blood immunophenotyping. Fresh EDTA-anticoagulated peripheral blood (50 ul) are 
stained with  the following conjugated monoclonal antibody combination in 8 color 
multiparametric flow cytometry (FITC, fluorescein isothiocyanate/PE, phycoerythrin/ PerCP-
Cy™5.5, peridinin-chlorophyll proteins-cychrome 5.5 /PE-Cy™7, PE-cyanine dye 7/APC, 
allophycocyanin/ BD™ APC-H7, allophycocyanin-H7/ V450, BD Horizon™ V450 /V500, BD 
Horizon™V500:  CD3/(CD16 and CD56)/CD4/CD19/CD38/CD8/CD20/CD45 in TruCount tubes. 
After 10 minutes incubation at room temperature (RT), blood is lysed with 2 ml lysing solution 
(BD Pharmlyse 1X) for 5 minutes and 250000 lymphocytes are acquired in a BD FACSCanto II 
cytometer. T lymphocytes (CD3+), T cell subsets (CD3+, CD4+ CD8neg and CD3+, CD8+, 
CD4neg), B lymphocytes (CD19+, CD20+), NK cells (CD3-, CD16+, CD56+ and CD3-, CD16+, 
CD56-)27
 
are evaluated by using  FACS DIVA software. Based on CD45 expression in a CD45 vs 
side scatter (SSC) a leukocyte gate is drawn to include granulocytes (CD45+/high SSC), 
monocytes (CD45/medium SSC), and lymphocytes (CD45+/low SSC). Results are expressed as 
leukocytes and lymphocytes counts, % of lymphocytes and % of monocytes of the total 
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leukocytes. Lymphocyte populations are expressed as % of total leukocytes  % lymphocytes 
and absolute counts (N/mmc).  
To study antigenic expression describing maturation, activation, disfunction, senescence of the 
T cell compartment and maturation of NK cells, blood (2ml) is bulk lysed with 15 ml lysing 
solution (BD Pharmlyse 1X) for 10 min, centrifuged at 1500 rpm, washed once with 5 ml PBS-
1%FCS, 0,1% NaN3 (PBS) and the pellet resuspended in PBS at 20 x 106/ml. Cells (50ul) are 
incubated with the following conjugated monoclonal antibody combinations: 1) 
CD45RA/CD62L/CD3/CD27/CD28/CD8/CD4/PD1, 2) CD45RA/CD62L/ 
HLADR/CD25/CD38/CD8/CD4/PD1, 3)CD57/CD45RO/CD27/CD28/CD8/ - /CD45, 4) 
CD57/CD16/CD3/CD56/-/CD14/-/CD45.  
 All antibodies are purchased from Becton Dickinson (San José, CA). 
Differential expression of CD45RA, CD62L, CD27 and CD28 is used to identify maturation 
subsets of CD4 and CD8 T cell populations (CD3+, CD4+ or CD8+) as shown in Table I-S 
(Supplementary Materials). 
The activation markers CD25, HLADR, CD38 are studied on naïve (CD45RA+, CD62L+) versus 
non naïve CD8 and CD4 T cells. Dysfunction (previously called “exhaustion”) is studied by the 
expression of inhibitory receptor PD-1 by gating on the various differentiation subsets based 
on CD45RA and CD62L expression levels and on activation markers (Legat et al, 2013).  
NK cells (CD56+CD3-/CD56-CD16+CD3-) are further characterized in four subsets: 
CD56brightCD16neg/dim (immature), CD56dimCD16bright / CD56negCD16bright (mature), CD56dimCD16dim 
(unconventional NK cells). For a fine analysis of NK cells Kaluza software (v.2.1, Beckman 





Dichotomous variables were compared using the Chi-Square test or by Fisher’s exact test when 
necessary. Continuous variables were compared using Student’s T test, or if normal 
distribution could not be confirmed, by Wilcoxon’s rank test.20  
Overall Survival (OS) was calculated from the time of transplantation until death by any cause, 
or last follow-up.  
Survival curves were built using the Kaplan Meier method, and univariate survival analysis was 
performed using the Log-rank test.20  
All statistical analyses, except competing risk analysis, were performed using IBMSPSS v22© 
running on a Debian (Linux) operating system. 




Eight R/R HL patients have been treated so far with ALI + nivolumab in this feasibility trial. All 
patients had failed to achieve CR with first and second line chemotherapy and progressed 
during BV therapy. Median age was 28.5 years (range 18-56). PET scan before ASCT showed 
progressing disease in all patients, with multiple-extra nodal involvement in 6/8. Two 
additional patients who achieve CR with salvage chemotherapy were enrolled in the control 
group and received ALI alone. Patient’s features are provided in Table I. All patients underwent 






During ASCT, patients experienced the following adverse events correlated to ASCT: fever of 
unknown origin in 4/10 patients, grade 2-3 mucositis in 6/10 patients, sepsis in two/ten 
patients. 
No grade 3 or 4 adverse events related to ALI or nivolumab were recorded in the first four 
patients, so that the other patients received the first ALI at the increased dose of 1x105 
CD3+/kg, without any complication. In the whole study, no infectious complications or other 
adverse events were observed during ALI +/- nivolumab therapy, in particular, no patient 




Our preliminary results show that ALI allowed to achieve significantly quicker immune-
recovery in all patients, in terms of absolute CD3+ count, if compared to historical HL patients 
receiving the same conditioning without ALI (p <0.05), especially in the T-lymphocyte effector-
memory compartment (p<0.03).  
Mature/cytotoxic NK cells (Figure 3) and naïve CD8+ cells (data not shown) showed a 
significant increase after ALI and  CI (p <0.03 and p<0.05, respectively). Nivolumab 
administration was followed by a modest and transient increase in T-effector-memory 
population (data not shown). 
We analyzed the development of NK cells in all 10 enrolled patients (Figure 4). Our data 
suggest that after ASCT, as expected, NK cells are the first lymphoid population detectable in 
peripheral blood. Interestingly, a faster expansion/reconstitution of NK cells displaying a 
highly differentiated surface phenotype was observed in the treatment cohort. In detail, 
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different patterns of NK-cell development could be identified. Indeed, starting from one 
month after transplantation, in the group of patients undergoing ALI plus post-ASCT 
nivolumab, a relevant fraction of NK cells displayed a mature phenotype characterized by 
CD56dimCD16bright expression (Figure 4). On the contrary, in patients undergoing ALI without 
early post-ASCT nivolumab (control group), NK cells were characterized by a more immature 
phenotype (high frequencies of CD56brightCD16neg NK cells) even at late time points (three 
months) after transplantation (Figure 4). In addition, in patients undergoing ALI + nivolumab, 
an aberrant and hyporesponsive subset of mature NK cells (namely CD56negCD16+), 
reminiscent of that described in patients with viremic CMV/HIV, was detected. Of note, this 
subset was absent in the control group (Figure 4). CMV DNA was assessed two times a week 
during all study period in all patients, performed by standard RT-PCR diagnostic test, and was 
always found to be undetectable in all patients. Finally,  peripheral blood from patients 
undergoing ALI + nivolumab was enriched in unconventional CD56dimCD16dim NK cells (Figure 
4a). A phenotypically similar subset of NK cell,  endowed with multifunctional activity 
(including potent killer and IFN-gamma producing capacity), was found in the bone marrow 
both of healthy children and of pediatric leukemic patients. 
 
Clinical Results 
Early response assessment performed after cycle 2 showed a negative PET in all patients and a 
complete CT response in 5/8. End of treatment evaluation showed complete PET and CT 
response in all patients. Three patients were bridged to HSCT and are alive, in ongoing CR and 
free of graft- versus- host disease (GVHD) at the time of analysis.  Three of the remaining 
patients refused HSCT, one patient did not find a donor while one patient had recently 
completed the procedure. All of them are alive and disease free after a median follow-up of 20 
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months (95% IC 16.58-24.56 months). 
Detailed therapeutic outcome is provided in Table II. 
 
Discussion 
The results of this feasibility study suggest that early post-ASCT administration of nivolumab 
supported by ALI is safe and highly effective in R/R HL patients. The combination of ALI and 
nivolumab may significantly improve the results of either single anti-PD-1 agent therapy or 
ASCT performed in patients with active disease.10,11,20  Armand et al. reported that 
pembrolizumab administration as post-ASCT consolidation in HL patients achieving at least PR 
before transplant, but considered at high risk of relapse resulted in a significant improvement 
of PFS.11 In our study, we explored the clinical benefit of nivolumab in the worse setting of  
truly refractory HL patients that are usually not considered candidate for ASCT. The high risk of 
early progression and the expected severe post-transplant immune suppression in these 
heavily pretreated patients, prompted us to plan pre-emptive nivolumab supported by ALI.21 
Post-ASCT ALI was very well tolerated and allowed a quick recovery of selected lymphocyte 
subsets.21 The impressive CR rate may be explained by the synergistic effect of the deep and 
rapid cytoreduction following ASCT conditioning and the immune response triggered by early 
CI therapy supported with ALI.  It has been widely reported that HSCT may provide a 
substantial contribute to cure advanced stage refractory HL patients if performed in CR.22 The 
high activity and the good tolerability of our strategy may therefore allow more refractory 
patients to enter CR and benefit from HSCT. Indeed, three patients in our cohort were able to 
receive allo transplant in a CR status. Nevertheless, regardless of subsequent HSCT, all enrolled 
patients maintain CR after discontinuation of immunotherapy, that was limited to 4 doses of 
nivolumab instead of standard until progression schedule.10 With the limitation of the small 
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number of patients and the relatively short follow up period, a shorter duration of CI therapy 
did not result in a worse survival.10 In this view a lower cumulative dose of nivolumab may 
contribute in lessening the risk of GVHD, which is very high in patients receiving allo-SCT after 
CI therapy.23 
The observation of a significant expansion of the mature/cytotoxic NK compartment during 
ALI+nivolumab treatment suggests that NK cells may play a significant role in the anti-
lymphoma response in this setting and is consistent with the observed trend for NK cell 
expansion in Armand et al study.11 Differently from what is observed in solid tumors Reed 
Sternberg (RS) cells, albeit expressing PD-1 ligand, show an HLA class I down-regulation, 
hampering the possibility of a cytotoxic CD8+- mediated killing.10,11,16,17 In this view, it has 
been recently reported that not only T-lymphocytes, but also NK cells express the PD-1 
receptor.9,24 Taken together, these observations suggest a key role for NK cells in response to 
PD-1 blockade in HL, as these innate cells kill tumor cell targets not expressing HLA class I 
molecules and, once activated, release high amount of pro-inflammatory cytokines that can 
shape other immune cell responses. 24-26  
Moreover, we documented a quicker NK cell maturation in patients receiving both ALI and 
nivolumab, compared to the control cohort. In physiological conditions, human NK cells 
include different cell subsets corresponding to different stages of NK cell differentiation.27 
CD56bright CD16neg/dim NK cells (the major subset of NK cells in secondary lymphoid tissues) are 
considered as precursors of CD56dim CD16pos NK cells and have been usually considered as 
“regulatory NK cells”. On the other end, CD56dim NK cell population is the most represented in 
peripheral blood and is considered as the “cytotoxic population”. The terminally differentiated 
phenotype of CD56dim cells is marked by the expression of the CD57 molecule and high levels 
of CD16.26,27 After HCMV infection/reactivation, an increased proportion of terminally 
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differentiated CD57+ NK cells, characterized by high expression of NKG2C, is induced (the so-
called “adaptive” NK cells). Interestingly, unknown cofactors associated with HCMV infection 
may induce the generation of an additional type of fully mature NK cells characterized by the 
expression of the inhibitory receptor PD-1 (not necessarily co-expressed with NKG2C). These 
cells, called PD-1+ NK cells, are marked by compromised effector functions against tumor cells 
expressing PD-1 ligands. Notably, this impaired antitumor NK cell activity can be partially 
restored by antibody-mediated disruption of PD-1/PD-L interaction.8,25,27 
A remarkable acceleration of NK cell maturation was described also in leukemic patients 
receiving different types of allograft (i.e. receiving UCBT or CD34+ haplo-HSCT or T/B cell-
depleted HLA-haploidentical HSCT containing variable numbers of donor-derived NK cells and 
γ/δ+ T cells). In all these recipients, CMV infection/reactivation favored the preferential 
expansion of highly differentiated NK cells and their persistence overtime.28 However, our 
patients resulted always negative for CMV, by PCR assessment, thus this NK cell expansion is 
not related to CMV infection/reactivation. These observations suggest a possible critical role 
for anti-PD-1 agents in controlling NK cell maturation/development. 
In this view, our data support the idea that lymphocyte repletion during early post-ASCT anti-
PD-1 consolidation may lead to a rapid accumulation of mature/cytotoxic CD56dimCD16bright NK 
cells, with anti-neoplastic and anti-infective activity.  
If a pivotal role of NK cells in CI clinical response in HL will be confirmed, this therapeutic 
strategy may pave the way to further innovative approaches, such as supporting CI therapy 
with positively selected autologous NK cells. Alternatively, highly purified NK cells from 
selected haploidentical donors may be used, considering that NK cells, differently from T-cells, 
do not induce GvHD.28-30  
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8/8 PD IV: 8/8 
Multiple in 7/8 
Single in 1/8 




PD IVB Lung, liver 











PD IVA Lung 




PD IVB Lung, liver 
Patient #5 22 F IVB 
6xABVD-> PD 
3xBeGeV-> PD 








PD IVB Lung, bone 














Control #1 52 F IIB 
2xABVD-> PR 
4xIGeV-> CR 
CR - - 
Control #2 34 F IIIA 
6xABVD-> PD 
4xIGeV-> CR 






Table II: Therapy Outcome after ALI / nivolumab 

















Donor and Source of  
Allogeneic SCT 
Disease and 




PR: 2/8 PR 
CR: 6/8 CR 




Haploidentical BM: 2/3 
HLA identical sibling BM: 1/3 
Alive and CR: 8/8 
Patient #1 CR CR CR CR YES CR Haploidentical, BM Alive and CR 
Patient #2 CR CR CR CR NO - - Alive and CR 
Patient #3 CR CR CR CR NO - - Alive and CR 
Patient #4 CR CR CR CR NO - - Alive and CR 
Patient #5 PR CR CR CR YES CR 
HLA-identical sibling, 
BM 
Alive and CR 
Patient #6 PR CR CR CR NO - - Alive and CR 
Patient #7 PR CR CR CR YES CR Haploidentical, BM Alive and CR 
Patient #8 CR CR CR CR NO - - Alive and CR 





























A: Development of NK cells in patients affected by R/R HL undergoing ASCT and receiving ALI + 
nivolumab (left panel A) or ALI alone (right panel A). 
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LYMPHOCYTE APHERESIS, CRYOPRESERVATION AND THAWING 
The unstimulated lymphocyte apheresis procedure has been performed in steady state (e.g. 
patient must not have received any chemotherapy or steroids in the last 14 days) by 
processing a blood volume of about 5 liters, with a single-needle discontinuous flux 
machine. 
The lymphocyte aphaeresis arrived to the Cell Factory from the Collection Center with 
attached complete blood count (CBC) of the product and one accompanying test tube. The 
test tube has been assessed for the CD3+ count at flow cytometry. 
1 ml of heparin sodium was added to the product and, if necessary, the cell suspension has 
been dilute with physiological solution and 5% final of Human Albumin up to the final 
freezing volume. Volume has been calculated by maintaining a cell concentration equal to 
50x106/ml.  
The cryoprotectant used is dimethyl sulfoxide(DMSO) 10% ; the product has been 
immediately transferred into 4-ml cryopreservation tubes and frozen at controlled-rate 
freezer (Ice cube SyLab). 
After freezing procedures, samples have been stored in a liquid nitrogen cryo-container 
until the reinfusion, under temperature control with H24 remote alarms. 
Blood cultures (BCs)for aerobic, anaerobic and fungi germs have been carried out on the 
final product.  
The target aphaeresis quantity of CD3+ cell has been minimum of 5x108/kg, if target dose 
has not been reached, a second unstimulated apheresis has been performed. 
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The thawing of the required dose of lymphocytes took place at the cryopreservation 
laboratory using a thermo stated bath at 37° C. In order to limit the DMSO toxicity, the 
thawed volume has been diluted 1: 1 with 0.9% Sodium chloride in a sterile environment. 




ASCT conditioning has been performed according to conventional FEAM high dose 
chemotherapy (Fotemustine 150 mg/sqm days -7 and -6, Etoposide 200 mg/sqm + 
Cytarabine 400 mg/sqm days -5 to -2, Melphalan 140 mg/sqm day -1). A minimum of 3 x 
106/kg CD34+ autologous stem cells have been re-infused on day 0 in all patients. 
Granulocyte stimulating factor (G-CSF) has been administered from day 3 until the 
complete granulocyte recovery (i.e. ANC >2000/mmc). All patients achieved complete 





Table I-S: T-Lymphocytes subpopulation definitions 
  % CD8 cells in 
PB of healthy 
individuals 
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EM RAINT CD45RA+/-, CD62Lneg, 
CD27neg o basso, CD28neg 
2-18% 0,2-1,8 
EM RA+ CD45RA+, CD62Lneg, CD27+, 
CD28+ or CD28neg 
2-18% 0,2-1,8 
Effectors (E) CD45RA++, CD62Lneg, 
CD27neg, CD28neg 
2-53% 0,2-5 
 
